Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy

Concurrent chemoradiotherapy and IMRT were the most common radiotherapy approaches. Higher mean lung radiotherapy dose and prior COPD were associated with higher SP risk during consolidation durvalumab for unresectable stage III NSCLC.

Authors

Institutions

Publication Details

Journal
Clinical and Translational Radiation Oncology
Published
2026-02-24
DOI
https://doi.org/10.1016/j.ctro.2026.101138
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy

Daniel C. Christoph, Vilde Drageset Haakensen, Yao Qiao, Hans Jm Smit et al.
Clinical and Translational Radiation Oncology
Lung Cancer Diagnosis and Treatment
article

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy

Daniel C. Christoph, Vilde Drageset Haakensen, Yao Qiao, Hans Jm Smit, Bar J, Mor Moskovitz, Pratibha Chander, Rainer Fietkau, Steven Kao, Michel M. Van Den Heuvel, Piet Vercauter, John K. Field, Jolyon Faria, Andrea R. Filippi, Benjamin Solomon, Fiona McDonald, Solange Peters, Francoise Mornex, Nicolas Girard, Marina Chiara Garassino
article en

Abstract

Concurrent chemoradiotherapy and IMRT were the most common radiotherapy approaches. Higher mean lung radiotherapy dose and prior COPD were associated with higher SP risk during consolidation durvalumab for unresectable stage III NSCLC.

Clinical and Translational Radiation OncologyVol. 58
AstraZeneca (United Kingdom) (GB), Oslo University Hospital (NO), Royal Marsden NHS Foundation Trust (GB), Radboud University Nijmegen (NL), University of Liverpool (GB), The University of Melbourne (AU), Universidad de Alcalá (ES), Université de Versailles Saint-Quentin-en-Yvelines (FR), University of Pavia (IT), Université Paris-Saclay (FR), Sheba Medical Center (IL), Peter MacCallum Cancer Centre (AU), Rambam Health Care Campus (IL), Roy Castle Lung Cancer Foundation (GB), Centre Hospitalier Universitaire Vaudois (CH), Radboud University Medical Center (NL), University of Chicago (US), Universitätsklinikum Erlangen (DE), Chris O’Brien Lifehouse (AU), Onze Lieve Vrouwziekenhuis Hospital (BE), Hôpital Lyon Sud (FR), Institut du Thorax (FR), AstraZeneca (United States) (US), Policlinico San Matteo Fondazione (IT), Rijnstate Hospital (NL), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Evangelisches Krankenhaus Königin Elisabeth Herzberge (DE), Institut Curie (FR)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Regeneron Pharmaceuticals, Novocure, Les Laboratories Pierre Fabre, Mirati Therapeutics, BeiGene, Incyte, Revolution Medicines, Natera, PharmaMar, Ipsen, LEO Pharma, Genentech, Chugai Pharmaceutical, Foundation Medicine, Daiichi Sankyo Europe
Life below water
Openalex Percentile: Top 46%
Lung Cancer Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.